AnaptysBio, Inc.

Contributing Author

Recent Articles by AnaptysBio, Inc.

Nov-25	Anaptys Announces Participation in December Investor Conferences ANAB GlobeNewswire
Nov-21	Anaptys Announces $100 Million Stock Repurchase Plan ANAB GlobeNewswire
Nov-21	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary ANAB GlobeNewswire
Nov-10	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis ANAB GlobeNewswire
Nov-04	Anaptys Announces Participation in November Investor Conferences ANAB GlobeNewswire
Nov-04	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire
Oct-29	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation ANAB GlobeNewswire
Oct-13	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 ANAB GlobeNewswire
Sep-29	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 ANAB GlobeNewswire
Sep-29	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 ANAB GlobeNewswire
Aug-27	Anaptys Announces Participation in September Investor Conferences ANAB GlobeNewswire
Aug-06	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire
Jun-03	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA ANAB GlobeNewswire
May-27	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 ANAB GlobeNewswire
May-05	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update ANAB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.